Core Concepts
SSRIs and anti-amyloid drugs may increase bleeding risk in AD patients.
Abstract
The content discusses the potential risks associated with prescribing anti-amyloid medication to Alzheimer's disease (AD) patients who are also taking selective serotonin reuptake inhibitors (SSRIs). Here is a breakdown of the key points:
Caution Urged: Clinicians advise caution when prescribing anti-amyloid drugs to AD patients on SSRIs due to potential bleeding risks.
Serotonin Effects: SSRIs can interfere with hemostasis, leading to increased bleeding risk.
Recommendations: Special attention is needed for patients on SSRIs, especially those with microhemorrhages.
Lecanemab Risks: Anti-amyloid drugs like lecanemab can cause amyloid-related imaging abnormalities (ARIA), increasing bleeding risk.
Appropriate Use: Recommendations for lecanemab use suggest close monitoring for patients on SSRIs or antiplatelet treatment.
Clinical Management: High prevalence of AD patients on SSRIs raises questions about appropriate clinical management.
Antidepressant Risks: Considerations for the risk of hemorrhage with different types of antidepressants in AD patients.
Data Gap: Lack of data on the relationship between monoclonal antibodies, antidepressants, and hemorrhage risk.
Future Adjustments: Monitoring ongoing research to potentially adjust recommendations based on emerging data.
Stats
SSRIs decrease platelet aggregability and activity.
Incidence of ARIA-H with lecanemab was 17.3% in early AD patients.
32% of eligible lecanemab patients were taking SSRIs.
11.4% of AD patients evaluated were eligible for lecanemab.
Tricyclic antidepressants have a lower risk of hemorrhage compared to SSRIs.
Quotes
"Drugs with the highest degree of serotonin reuptake inhibition...are frequently associated with increased bleeding." - Beatriz Pozuelo Moyano
"The first 30 days after starting an SSRI is a 'crucial' risk period for intracerebral hemorrhage." - Beatriz Pozuelo Moyano
"Depressed patients might have more cerebral vascular disease and more hemorrhage through mechanisms unrelated to ARIA." - Jeffrey Cummings